852475-26-4
852475-26-4 structure
- Name: MC1568
- Chemical Name: (E)-3-[4-[(E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-N-hydroxyprop-2-enamide
- CAS Number: 852475-26-4
- Molecular Formula: C17H15FN2O3
- Molecular Weight: 314.311
- Catalog: Biochemical Inhibitor Epigenetics HDAC inhibitor
- Create Date: 2016-07-01 14:06:46
- Modify Date: 2024-01-09 06:03:12
-
MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor, used for cancer research.
| Name | (E)-3-[4-[(E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-N-hydroxyprop-2-enamide |
|---|---|
| Synonyms |
MC1568
cc-402 (2E)-3-{4-[(1E)-3-(3-Fluorophenyl)-3-oxo-1-propen-1-yl]-1-methyl-1H-pyrrol-2-yl}-N-hydroxyacrylamide S1484_Selleck (2E)-3-{4-[(1E)-3-(3-fluorophenyl)-3-oxoprop-1-en-1-yl]-1-methyl-1H-pyrrol-2-yl}-N-hydroxyprop-2-enamide (E)-3-(4-((E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrol-2-yl)-N-hydroxyacrylamide 2-Propenamide, 3-[4-[(1E)-3-(3-fluorophenyl)-3-oxo-1-propen-1-yl]-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-, (2E)- MC-1568,MC1568 |
| Description | MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor, used for cancer research. |
|---|---|
| Related Catalog | |
| Target |
HDAC |
| In Vitro | MC1568 arrests myogenesis by decreasing myocyte enhancer factor 2D (MEF2D) expression, by stabilizing the HDAC4–HDAC3–MEF2D complex, and paradoxically, by inhibiting differentiation-induced MEF2D acetylation[1]. MC1568 and MC1575 inhibits IL-8 levels and cell proliferation in either unstimulated or PMA-stimulated melanoma cells. They acts by suppressing c-Jun binding to the IL-8 promoter, recruitment of histones 3 and 4, RNA polymerase II and TFIIB to the c-Jun promoter, and c-Jun expression[2]. MC1568 interferes with the RAR- and PPARγ-mediated differentiation-inducing signaling pathways. In F9 cells, this inhibitor specifically blocks endodermal differentiation. In 3T3-L1 cells, MC1568 attenuates PPARγ-induced adipogenesis[3]. |
| In Vivo | MC1568 shows an apparent tissue-selective HDAC inhibition. In skeletal muscle and heart, MC1568 inhibits the activity of HDAC4 and HDAC5 without affecting HDAC3 activity, thereby leaving MEF2–HDAC complexes in a repressed state[1]. MC1568 increases mortality and lesion volume and did not improve functional outcome. In addition, MC1568 decreases microtubule associated protein 2, phosphorylated neurofilament heavy chain and myelin basic protein immunoreactivity in the periinfarct cortex[4]. |
| Cell Assay | For proliferation studies, 15 ×103 cells are seeded onto 24-well plates in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 3 mM L-glutamine, 2% penicillin/streptomycin. After 24 h, untreated or HDACis-treated cells are incubated with either vehicle alone or PMA (50 ng/mL) for 6 h, and cell proliferation is evaluated by MTT assay and by cell number counting[2]. |
| Animal Admin | Adult male Wistar rats (n=15-17/group) are subjected to 2 h MCAO and orally gavaged with MC1568 (a selective class IIa HDAC inhibitor), SAHA (a non-selective HDAC inhibitor), or vehicle-control for 7 days starting 24 h after MCAO. A battery of behavioral tests is performed. Lesion volume measurement and immunohistochemistry are performed 28 days after MCAO[4] |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H15FN2O3 |
| Molecular Weight | 314.311 |
| Exact Mass | 314.106659 |
| PSA | 74.82000 |
| LogP | 2.91 |
| Appearance | orange |
| Index of Refraction | 1.572 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: ≥10mg/mL |
